Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2001

View Archived Issues

Study questions cardiovascular safety of COX-2 inhibitors

Dimethaid highlights Pennsaid progress during fiscal 2001

Clinical programs at NPS continue steady progression during Q2

Devacade shown to enhance pain relief in phase II clinical trial

Phase I trial of Herzyme commences in breast and ovarian cancer

Tostrelle shows promise as treatment for female sexual dysfunction

Oxagen and Cerylid initiate gene discovery program for endometriosis

Motorola Life Sciences and SNP Consortium announce key alliance

Northfield seeks FDA approval of PolyHeme blood substitute

FDA accepts Orphan Medical's proposed response plan regarding Xyrem NDA

Antisoma takes on development of promising vascular targeting agent from the CRC

GW-432042: a potent and selective iNOS inhibitor debuts at ACS meeting

Collaborative investigations by Pfizer and Neurogen yield pyrazolopyrimidine NPY antagonists

Potent and selective CCR2B receptor antagonist described by GlaxoSmithKline

Novel adenosine kinase inhibitors with improved half-life and oral bioavailability

Nippon Kayaku withdraws central muscle relaxant from approval process

KW-4490 advances to clinical trials as potential antiasthmatic

Potential new antidepressants described at ACS meeting: AMPA receptor potentiators

Neuromuscular blockade reversed by cyclodextrin-based compounds

Anti-factor D MAb from Tanox reduces systemic inflammatory response in cardiopulmonary bypass model

Add-on therapy with CHF-1035 associated with improvement in clinical indicators of heart failure

Two recent patents cover P2X7 receptor antagonists and their potential uses

HMR-1556 selectively blocks slow delayed rectifier potassium channel in cardiac myocytes

JT describes new agents for hepatitis C

Sanofi-Synthelabo claims new series of beta3-adrenoceptor agonists

Safe and effective glucose-lowering agents prepared at Kyowa Hakko

Dipeptide HIV protease inhibitors in development at Japan Energy

Eisai describes new neovascularization inhibitors in patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...